Q1 2026 MedPlus Health Services Ltd Earnings Call Transcript
Key Points
- Medplus Health Services Ltd (BOM:543427) opened 124 new stores in the current quarter, contributing to a net addition of 101 stores.
- The company has operationalized six out of ten additional warehouses, enhancing its supply chain capabilities.
- Private label sales have increased significantly, with private label pharma sales rising from 7.9% in Q1 FY '24 to 20.4% in Q1 FY '26.
- The diagnostic segment showed strong growth, with revenue increasing to INR302.9 million and an operating EBITDA margin of 13.6%.
- The company plans to add 600 new stores in fiscal '26, indicating a strong growth trajectory.
- Same-store sales growth (SSG) has been lackluster, with some de-growth observed, raising concerns about organic growth.
- There were 23 store closures in the quarter, including eight franchisee conversions, which may indicate challenges in certain locations.
- The company faces supply chain and warehousing challenges, impacting sales and fill rates in some regions.
- The private label push has led to some customer dissatisfaction, as not all customers are willing to switch from branded products.
- The growth in private label sales has resulted in a trade-off with top-line growth, as private label products are sold at a discount compared to branded generics.
Ladies and gentlemen, good day and welcome to the MedPlus Health Services Limited Q1FY '26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to [Mr. DRN Srinivas.]
Thank you and over to you, sir.
Thank you, Sagar. Good evening, everyone. On behalf of MedPlus, it's my utmost pleasure to welcome you all to the MedPlus Q1 FY '26 earnings conference call to discuss the financial results of MedPlus for the first quarter FY '26, which were announced earlier.
We have with us today, the senior management team represented by Mr. Madhukar Reddy Gangadi, CEO and MD and Mr. Sujit Mahato, CFO. Before we begin, I would like to mention that some of the statements made in today's discussion may be forward-looking in nature and may involve risks and uncertainties.
Please note the disclaimer mentioning these risks and uncertainties on slide 1 of the investor presentation shared with all of you earlier. Documents relating to our financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
